Zogenix, Inc: Zogenix Provides Corporate Update and Reports

Total revenue of $26.6 million in the fourth quarter and $81.7 million for the full yearFINTEPLA® net product sales of $23.5 million in the fourth quarter and $74.7 million for the full year Announced

Related Keywords

Germany , Japan , United States , France , Japanese , American , Porter Novelli , Trish Mccall , Tevard Biosciences , Stephenj Farr , Brian Ritchie , Us Securities Exchange Commission , Nippon Shinyaku Co Ltd , Lifesci Advisors , Zogenix Access Program , Drug Application To Japan Ministry Of Health , Drug Administration , Zogenix Inc , American Epilepsy Society Annual Meeting , Exchange Commission , Japanese Ministry Of Health , European Medicines Agency , Zinc Merger Sub Inc , Priority Review , Supplemental New Drug Application , Lennox Gastaut Syndrome , New Drug Application , Access Program , Japanese Ministry , American Epilepsy Society Annual , Fourth Quarter , Results Compared , Year Ended , Investor Relations , Zinc Merger Sub , Recommendation Statement , Merger Sub , Private Securities Litigation Reform Act , Zogenix , Rovides , Corporate , Update , Reports , Fourth , Quarter , Bull , Ear , 021 , Financial , Results ,